Advancing Gene Therapy for Glanzmann’s Thrombasthenia: Urgent Support Needed

Gene Therapy for Glanzmann's Thrombasthenia

March 26, 2024


“We are currently making significant strides in our testing of the clinical vector, yielding promising results thus far. These efforts are crucial in generating the preliminary data necessary to pave the way for our application and subsequent approval of a clinical trial for gene therapy for Glanzmann’s Thrombasthenia (GT). Additionally, we are in the process of completing an application for a pre-investigational drug (IND) meeting with the FDA.

I’m pleased to share that the budget allocation for gene therapy at the Medical College of Wisconsin has been approved for the fiscal year 2024-2025. While we’ve been fortunate to receive generous support from the GT community in the past, this year, we are facing a reduction in donations, leading to a significant decrease in our budget compared to previous years. Now more than ever, we rely on the support of individuals within the GT community to propel our research forward.

If you have ever contemplated contributing to our efforts to advance toward a clinical trial, I urge you to consider donating at this pivotal moment. Despite the challenging economic climate, your support is integral to our ability to continue our work and make strides in the field of gene therapy.

Thank you for considering taking an active role in finding a cure for GT.”

– David A. Wilcox, PhD

For direct support, send checks made to the Medical College of Wisconsin and in the designation state “For Dr. Wilcox Glanzmann Thrombasthenia Research” to
David A. Wilcox , PhD
Department of Pediatrics, MFRC 6014
Medical College of Wisconsin
8701 Watertown Plank Road

Milwaukee, WI 53226

or at Where asked for Gift Designation, choose other then indicate Department of Pediatrics, Dr. David Wilcox Glanzmann’s Thrombasthenia Research.